Former Chief Financial Officer · GYRE THERAPEUTICS, INC. (GYRE)

Clinton Musil

A named executive officer of GYRE THERAPEUTICS in every fiscal year CompBrief holds from FY2020 to FY2021. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$649,624

Salary $389,734Stock awards $0

FY2020: $966,912

3rd of 5 named executive officers at Gyre Therapeutics by FY2021 total.

5 named officers on file for GYRE THERAPEUTICS, FY2021

Clinton Musil’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how GYRE THERAPEUTICS’s whole pay program stands against its peers

  • GYRE THERAPEUTICS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on GYRE→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed July 19, 2022 (DEF 14A).

Free

Get Clinton Musil’s full pay file as a PDF — free

More than this page: up to 10 years of Clinton’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Clinton Musil compensation by year

GYRE THERAPEUTICS Summary Compensation Table · all 2 fiscal years held
In US dollars, as GYRE THERAPEUTICS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021
Salary$197,691$389,734
Bonus$0$0
Stock awards$0$0
Option awards$696,142$239,890
Non-equity incentive$66,490$0
Pension and deferred compensation$0$0
All other$6,589$20,000
Total$966,912$649,624

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: GYRE THERAPEUTICS, INC. DEF 14A filed July 19, 2022, accession 0001140361-22-026309, and prior-year filings.

How this page was built: the GYRE THERAPEUTICS, INC. filed document, accession 0001140361-22-026309. Every figure is read from that document and cited to the page and table it appears in. Filed July 19, 2022.

$967K
$650K
FY20
FY21
SalaryNon-equity incentiveOption awardsAll other

GYRE THERAPEUTICS’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Nassim UsmanPresident and Chief Executive Officer$1,235,751
Grant BlouseChief Scientific Officer$736,694
Clinton Musil · this pageFormer Chief Financial Officer$649,624
M.B.B.Ch. Howard LevyFormer Chief Medical Officer$618,254
Seline MillerInterim Chief Financial Officer$313,339

The full GYRE THERAPEUTICS compensation record

free company brief

This page is one person within GYRE THERAPEUTICS's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are GYRE THERAPEUTICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Clinton Musil's compensation dossier · One-time report. No refunds.